摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

N-Furan-2-ylmethyl-2-phenylsulfanyl-acetamide | 380211-25-6

中文名称
——
中文别名
——
英文名称
N-Furan-2-ylmethyl-2-phenylsulfanyl-acetamide
英文别名
N-(furan-2-ylmethyl)-2-phenylsulfanylacetamide
N-Furan-2-ylmethyl-2-phenylsulfanyl-acetamide化学式
CAS
380211-25-6
化学式
C13H13NO2S
mdl
——
分子量
247.318
InChiKey
BPIASVWLNHWJTN-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.4
  • 重原子数:
    17
  • 可旋转键数:
    5
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.15
  • 拓扑面积:
    67.5
  • 氢给体数:
    1
  • 氢受体数:
    3

文献信息

  • INHIBITORS OF 15-HYDROXYPROSTAGLANDIN DEHYDROGENASE FOR STIMULATING PIGMENTATION OF THE SKIN OR SKIN APPENDAGES
    申请人:MICHELET JEAN-FRANCOIS
    公开号:US20110014250A1
    公开(公告)日:2011-01-20
    Inhibitors of 15-hydroxyprostaglandin dehydrogenase (15-PGDH), for example tetrazole, styrylpyrazole, phenylfuran, phenylthiophene, phenylpyrrazole, pyrazolecarboxamide, 2-thioacetamide and azo compounds, are useful for promoting or stimulating pigmentation of the skin and/or skin appendages and/or for preventing and/or for limiting depigmentation and/or whitening of the skin and/or skin appendages, notably for preventing and/or limiting canities.
    15-羟基前列腺素脱氢酶(15-PGDH)的抑制剂,例如四唑、苯乙烯吡唑、苯并呋喃、苯并硫吩、苯并吡唑、吡唑羧酰胺、2-硫代乙酰胺和偶氮化合物,可用于促进或刺激皮肤和/或皮肤附属物的色素沉着,或预防和/或限制皮肤和/或皮肤附属物的脱色和/或变白,特别是预防和/或限制白发。
  • Utilisation d'un inhibiteur de 15-hydroxy prostaglandine déshydrogénase pour favoriser la pigmentation de la peau ou des phanères
    申请人:L'Oréal
    公开号:EP1594438B1
    公开(公告)日:2013-07-17
  • NOVEL REGULATORS OF ALDEHYDE DEHYDROGENASE ALDH3A1 AND RELATED THERAPEUTIC METHODS
    申请人:Indiana University Research and Technology Corporation
    公开号:US20150202169A1
    公开(公告)日:2015-07-23
    Described herein are compositions and methods for the treatment of cancer, and in particular cancers characterized by a high level of ALD3H1 activity, which is associated with chemoresistance to cancer chemotherapeutic agents that are degraded by ALD3H1. The compositions described herein act as competitive inhibitors of ALD3H1 and thereby reduce breakdown of chemotherapeutics by this enzyme, and increase their efficacy for cancer treatment.
  • US7705041B2
    申请人:——
    公开号:US7705041B2
    公开(公告)日:2010-04-27
  • US8735445B2
    申请人:——
    公开号:US8735445B2
    公开(公告)日:2014-05-27
查看更多